RO7049389 + nucleoside analogue + peginterferon alfa

This is a **triple combination antiviral regimen** consisting of: - **RO7049389**, an investigational hepatitis B virus (HBV) core protein allosteric modulator (also called a "capsid assembly modulator"), - a **nucleoside analogue** (the precise agent can vary, but commonly tenofovir or entecavir, which inhibit the HBV polymerase), and - **peginterferon alfa** (pegylated interferon alfa, an immunomodulator that boosts the host antiviral response). This combination has been tested in clinical trials primarily for the treatment of **chronic hepatitis B** infection. The rationale is to combine direct-acting antivirals with an immunomodulatory agent to improve viral suppression and potentially induce functional cure. RO7049389 is developed by Roche/Genentech. Peginterferon alfa is marketed under brand names such as Pegasys or PegIntron.